Enzene Biosciences Teriparatide Biosimilar Obtains Marketing Authoriation in India
By EsqSocial Corporation 05/02/21
Enzene Biosciences Ltd., located in Pune, India, has announced that it has obtained marketing authorization from the Drug Controller General of India (DCGI) for its first biosimilar product in India. Enzene’s teriparatide biosimilar, indicated for the treatment of osteoporosis, will be marketed through Enzene’s holding company Alkem Laboratories, Ltd....
By: Goodwin